// App-Quantinova.ai

DMT53 : A Post Hoc Analysis of Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod in Phase 3 Trials

Researchers

Presenter

  • Sarah Harris

Principal Investigators

  • Harry Southworth

  • James K. Sheffield

  • Rachel Maddux

  • Jeffrey A. Cohen

Medical Centers

  • Mellen Center for MS Treatment and Research, Cleveland Clinic Cleveland OH United States

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • Cluster of differentiation 79A

  • Lymphocyte count

  • Immunoglobulin G

Drug/Treatment

  • Interferon

  • Ozanimod

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved